{
    "clinical_study": {
        "@rank": "26765", 
        "arm_group": {
            "arm_group_label": "BI 207127 + faldaprevir + Microgynon", 
            "arm_group_type": "Experimental", 
            "description": "Period A: Microgynon\u00ae;  Period B: Microgynon\u00ae  + FDV + BI 207127"
        }, 
        "brief_summary": {
            "textblock": "Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the\n      multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon\u00ae) in\n      healthy premenopausal female volunteers."
        }, 
        "brief_title": "Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy female subjects\n\n          -  Age 18 to 35 years (inclusive)\n\n          -  Body Mass Index 20-29.9 kg/m2\n\n          -  Use of hormonal contraception (i.e. oral contraceptives, hormonal contraceptive\n             vaginal ring, but not hormone-containing intrauterine devices, depot injections or\n             contraceptive implants)\n\n        Exclusion criteria:\n\n          -  Any relevant deviation from healthy conditions\n\n          -  Subject is assessed by the investigator as unsuitable for inclusion, for instance,\n             because considered not able to understand and comply with study requirements, or has\n             a condition that would not allow safe participation in the study\n\n          -  Positive pregnancy test, pregnancy or planning to become pregnant within 1 month of\n             study completion, or lactation\n\n          -  Any relevant finding of the gynaecological examination\n\n          -  Thrombotic predisposition according to thrombophilic testing\n\n          -  Existing or history of arterial thrombotic or embolic processes, conditions which\n             predispose to them e.g. disorders of the clotting processes, valvular heart disease\n             and atrial fibrillation\n\n          -  Existing or history of confirmed venous thromboembolism, family history of venous\n             thromboembolism, and other known risk factors for venous thromboembolism.\n\n          -  Relevant varicosis\n\n          -  No use of an additional contraceptive method from screening examination until 1 month\n             after last study drug administration (acceptable methods are considered to be barrier\n             methods, sexual abstinence, non-hormone-containing intrauterine device, or\n             vasectomisation for the male partner).\n\n        Use of hormone-containing intrauterine device, depot injection or contraceptive implants\n\n          -  Any history of relevant liver diseases (e.g. disturbances of liver function, jaundice\n             or persistent itching during a previous pregnancy, Dubin-Johnson syndrome, Rotor\n             syndrome, or previous or existing liver tumours)\n\n          -  AST (aspartate transaminase) and/or ALT (alanine transaminase) > 1.5 ULN (upper limit\n             of normal)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941615", 
            "org_study_id": "1241.31", 
            "secondary_id": "2013-000298-62"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 207127 + faldaprevir + Microgynon", 
                "description": "oral doses for 10 days (period B)", 
                "intervention_name": "faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 + faldaprevir + Microgynon", 
                "description": "oral doses for 23 days (period A+B)", 
                "intervention_name": "Microgynon\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 + faldaprevir + Microgynon", 
                "description": "oral doses for 10 days (period B)", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Levonorgestrel", 
                "Ethinyl Estradiol-Norgestrel Combination", 
                "Ethinyl estradiol, levonorgestrel drug combination", 
                "Ethinyl Estradiol"
            ]
        }, 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mannheim", 
                    "country": "Germany"
                }, 
                "name": "1241.31.2 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subjects", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCt,ss (area under the concentration-time curve of ethinylestradiol in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of ethinylestradiol in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "C24,ss (measured concentration of ethinylestradiol in plasma at steady state 24 hours after drug administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "AUCt,ss (area under the concentration-time curve of levonogestrel in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of levonogestrel in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }, 
            {
                "measure": "C24,ss (measured concentration of levonogestrel in plasma at steady state 24 hours after drug administration)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}